[toc]

- [Summaries](#summaries)
  - [Table 1: Virus Variants and Spike Mutations vs Monoclonal Antibodies](#table.1.virus.variants.and.spike.mutations.vs.monoclonal.antibodies)
  - [Table 2: Virus Variants and Spike Mutations vs Convalescent Plasma and Plasma from Vaccinated Persons](#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma.and.plasma.from.vaccinated.persons)
  - [Figure: Virus Variants and Spike Mutations vs Convalescent Plasma and Plasma from Vaccinated Persons](#figure.virus.variants.and.spike.mutations.vs.convalescent.plasma.and.plasma.from.vaccinated.persons)
- Raw data
  - [Spike variants and mutation combinations / monoclonal antibodies neutralization](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-variants-and-mutation-combinations-mab-neutralization)
  - [Spike variants and mutation combinations / plasma neutralization](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-variants-and-mutation-combinations-plasma-neutralization)
  - [Spike mutations _in vitro_ selection](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-mutation-invitro-selection-cp-and-mab)
- Individual study details
  - [Table S1: Neutralizing Sensitivity of Variants of Concern to Convalescent Plasma and Plasma from Vaccinated Persons](/page/susceptibility-data/plasma-variant/)
  - [Table S2: Neutralizing Sensitivity of Variants of Concern to Monoclonal Antibodies](/page/susceptibility-data/mab-variant/)
  - [Table S3: Neutralizing Sensitivity of Spike Mutations to Convalescent Plasma and Plasma from Vaccinated Persons](/page/susceptibility-data/plasma-mutations/)
  - [Table S4: Neutralizing Sensitivity of Spike Mutations to Monoclonal Antibodies](/page/susceptibility-data/mab-mutations/)
- [Supplementary data](#supplementary.data)
  - [Statistics of Published in vitro Neutralization Assays](#statistics.of.published.in.vitro.neutralization.assays)
  - [Spike Mutations Binding](#spike.mutations.binding)
  - [Spike Mutations Monoclonal Antibodies Escape](#spike.mutations.monoclonal.antibodies.escape)

[/toc]

## Summaries

### Table 1: Virus Variants and Spike Mutations vs Monoclonal Antibodies

Fold reduced neutralizing susceptibility to monoclonal antibodies in phase 3 clinical trials

[table compact,lastCompact]
table_mab
[/table]

- The fold change is the median value of samples, the subscript is the number of samples. “-“ indicates absence of susceptibility data. “\*“ indicates conflict between two research groups, with one showing high-level of reduced susceptibility especially using IC80 rather than IC50.
- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.526**: L5F, T95I, D253G, E484K, D614G, A701V. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G.
- Monoclonal antibody(mAb) abbreviations: **BAM**: Bamlanivimab/LY-CoV555, **CAS**: Casirivimab/REGN10933, **IMD**: Imdevimab/REGN10987, **CAS/IMD**: Casirivimab+imdevimab/REGN-COV2, **ETE**: Etesevimab/LY-CoV016/JS016/CB6, **CIL**: Cilgavimab/COV2-2130/AZD1061, **TIX**: Tixagevimab/COV2-2196/AZD8895, **TIX/CIL**: Tixagevimab+Cilgavimab, **BAM/ETE**: Bamlanivimab+Etesevimab, **SOT**: Sotrovimab/Vir-7831/S309.
- The color scheme indicates the fold-reduction in neutralization: <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span> – &lt;3-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span> – 3 to 9.9-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span> – ≥10-fold reduced susceptibility.


<!-- ### Figure 1: Virus Variants or Spike Mutations vs Monoclonal Antibodies

<section id="sec_mab-fold" class="figure-section wrap">

<div class="figure-image">

![Monoclonal antibodies](https://hivdb.github.io/covid-drdb-reports/susceptibility-data_files/figure-html/mab-fold-fig-1.png#!maxWidth=95%)

</div>

<div class="figure-caption">

Fold reduced _in vitro_ neutralization susceptibility to monoclonal neutralizing antibodies (mAbs) associated with three variants of concern (B.1.1.7, B.1.351, and P.1) and six spike amino acid mutations E484K, N501Y, L452R, K417N, N439K, and Y453F. B.1.1.7 contains N501Y plus two S1 N-terminal domain (NTD) deletions, three S1 C-terminal domain (CTD) mutations, and three S2-mutations. B.1.351 contains E484K and N501Y plus four S1 NTD mutations, two receptor binding domain (RBD) mutations, one S1 CTD mutation, and one S2 mutation. P.1 contains E484K and N501Y plus five S1 NTD mutations, one RBD mutation, two S1 CTD mutations, and two S2 mutations. Each of the _in vitro_ susceptibility experiments were performed using pseudovirus assays. Some of the pseudovirus assays performed with single amino acid mutations contained D614G while others did not. D614G has been reported to slightly increase neutralization susceptibility. The Y-axis indicates the log-fold reduction in susceptibility. Data are displayed for mAbs in advanced clinical trials and several additional prototypical mAbs with high-resolution 3-D structures and defined mechanisms of mAb-RBD binding.

<p>
The color scheme indicates the fold-reduction in neutralization: <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span> – &lt;3-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span> – 3 to 9.9-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span> – ≥10-fold reduced susceptibility.
</p>


</div>

</section> -->



### Table 2: Virus Variants and Spike Mutations vs Convalescent Plasma and Plasma from Vaccinated Persons

[table compact,lastCompact]
table_plasma
[/table]

- Convalescent plasma in all studies is presumed likely to have been obtained from persons infected with spike variants lacking mutations associated with reduced neutralization susceptibility.
- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G.


### Figure: Virus Variants and Spike Mutations vs Convalescent Plasma and Plasma from Vaccinated Persons

<section id="sec_plasma-fold" class="figure-section wrap">

<div class="figure-image">

![Convalescent and vaccine-recipient plasma](https://hivdb.github.io/covid-drdb-reports/susceptibility-data_files/figure-html/plasma-fold-fig-1.png#!maxWidth=95%)

</div>

<div class="figure-caption">

- Fold reduced _in vitro_ neutralization susceptibility to plasma from previously infected and vaccinated persons associated with variants of concern (B.1.1.7, B.1.351, P.1 and B.1.429/B.1.427), and two spike amino acid mutations E484K and N501Y.
- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G.
- The Y-axis indicates the number of plasma samples tested.
- “\*”: The study is using authentic virus assay.

<p>
The color scheme indicates the fold-reduction in neutralization: <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span> – &lt;3-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span> – 3 to 9.9-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span> – ≥10-fold reduced susceptibility. The histogram labels indicate the studies’ authors and plasma characteristics. BNT: BNT162b2; Mod: mRNA-1273; NVX: NVX-CoV2373; AZD: AZD1222. Each of plasma units were obtained approximately one month following vaccination except one study.
</p>


Studies:

- **Becker21**: [^Becker21#inline]
- **Brown21**: [^Brown21#inline]
- **Cele21**: [^Cele21#inline]
- **Chen21**: [^Chen21#inline]
- **Collier21**: [^Collier21#inline]
- **Dejnirattisai21**: [^Dejnirattisai21#inline]
- **Deng21**: [^Deng21#inline]
- **Edara21**: [^Edara21#inline]
- **Emary21**: [^Emary21#inline]
- **Faulkner21**: [^Faulkner21#inline]
- **Garcia-Beltran21**: [^Garcia-Beltran21#inline]
- **Greaney21**: [^Greaney21#inline]
- **Hoffmann21**: [^Hoffmann21#inline]
- **Hoffmann21b**: [^Hoffmann21b#inline]
- **Hu21**: [^Hu21#inline]
- **Jangra21**: [^Jangra21#inline]
- **Kemp21**: [^Kemp21#inline]
- **Liu21**: [^Liu21#inline]
- **Liu21b**: [^Liu21b#inline]
- **Madhi21**: [^Madhi21#inline]
- **Marot21**: [^Marot21#inline]
- **Moyo-Gwete21**: [^Moyo-Gwete21#inline]
- **Muik21**: [^Muik21#inline]
- **Planas21**: [^Planas21#inline]
- **Rees-Spear21**: [^Rees-Spear21#inline]
- **Shen21**: [^Shen21#inline]
- **Tada21**: [^Tada21#inline]
- **Tang21**: [^Tang21#inline]
- **Wang21**: [^Wang21#inline]
- **Wang21b**: [^Wang21b#inline]
- **Wang21c**: [^Wang21c#inline]
- **Wang21f**: [^Wang21f#inline]
- **Wibmer21**: [^Wibmer21#inline]
- **Widera21**: [^Widera21#inline]
- **Wu21**: [^Wu21#inline]
- **Xie21b**: [^Xie21b#inline]
- **Zhou21b**: [^Zhou21b#inline]

</div>

</section>


## Supplementary data

### Statistics of Published _in vitro_ Neutralization Assays

Numbers of published _in vitro_ neutralization assays according to spike mutations, type of plasma, and monoclonal antibodies


[table compact,lastCompact]
table_summary
[/table]

<div style="clear: both;" />

### Spike Mutations Binding

[table compact,lastCompact]
table_binding
[/table]

<div style="clear: both;" />


### Spike Mutations Monoclonal Antibodies Escape

[table compact,lastCompact]
table_escape
[/table]


<div style="clear: both;" />

